# Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies

> **NCT07644039** · PHASE1,PHASE2 · RECRUITING · sponsor: **PharmaMar** · enrollment: 119 (estimated)

## Conditions studied

- Advanced Malignancies

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** PM54

## Key facts

- **NCT ID:** NCT07644039
- **Lead sponsor:** PharmaMar
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05-21
- **Primary completion:** 2029-04-02
- **Final completion:** 2029-04-02
- **Target enrollment:** 119 (ESTIMATED)
- **Last updated:** 2026-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07644039

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07644039, "Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07644039. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*